Review



pd98059  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    MedChemExpress pd98059
    CAPN1 facilitated the osteogenic differentiation of hPDLSCs through the ERK signalling pathway . (A) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs with or without lentivirus transfection. (B) Quantification of the images in A. (C) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs following siRNAs treatment. (D) Quantification of the images in C. (E) Representative Western blot for PHLPP1 in hPDLSCs following siRNAs treatment and quantification of the images. (F) Quantification of the images in E. (G) Representative Western blot for PHLPP1 in hPDLSCs following Calpeptin treatment. (H) Quantification of the images in G. (I) Representative Western blot for CAPN1, ERK1/2, and p-ERK1/2 in hPDLSCs following <t>PD98059</t> or Calpeptin treatment. (J) Quantification of the images in J. (K) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following increasing NSC45586 doses treatment. (L) Quantification of the images in J. (M) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following siPHLPP1 treatment. (N) Quantification of the images in M. (O) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following si CAPN1 or si CAPN1 combined with NSC45586 treatment. (P) Quantification of the images in O. Mean ± SD was employed to express all data (ns P > .05, ∗ P < .05, ∗∗ P < .01, *** P < .001, **** P < .0001).
    Pd98059, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 502 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd98059/product/MedChemExpress
    Average 96 stars, based on 502 article reviews
    pd98059 - by Bioz Stars, 2026-02
    96/100 stars

    Images

    1) Product Images from "Calpain-1 Potentiates Periodontal Regeneration via PHLPP1-ERK-Driven Osteogenesis in Periodontal Ligament Stem Cells"

    Article Title: Calpain-1 Potentiates Periodontal Regeneration via PHLPP1-ERK-Driven Osteogenesis in Periodontal Ligament Stem Cells

    Journal: International Dental Journal

    doi: 10.1016/j.identj.2025.109309

    CAPN1 facilitated the osteogenic differentiation of hPDLSCs through the ERK signalling pathway . (A) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs with or without lentivirus transfection. (B) Quantification of the images in A. (C) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs following siRNAs treatment. (D) Quantification of the images in C. (E) Representative Western blot for PHLPP1 in hPDLSCs following siRNAs treatment and quantification of the images. (F) Quantification of the images in E. (G) Representative Western blot for PHLPP1 in hPDLSCs following Calpeptin treatment. (H) Quantification of the images in G. (I) Representative Western blot for CAPN1, ERK1/2, and p-ERK1/2 in hPDLSCs following PD98059 or Calpeptin treatment. (J) Quantification of the images in J. (K) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following increasing NSC45586 doses treatment. (L) Quantification of the images in J. (M) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following siPHLPP1 treatment. (N) Quantification of the images in M. (O) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following si CAPN1 or si CAPN1 combined with NSC45586 treatment. (P) Quantification of the images in O. Mean ± SD was employed to express all data (ns P > .05, ∗ P < .05, ∗∗ P < .01, *** P < .001, **** P < .0001).
    Figure Legend Snippet: CAPN1 facilitated the osteogenic differentiation of hPDLSCs through the ERK signalling pathway . (A) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs with or without lentivirus transfection. (B) Quantification of the images in A. (C) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs following siRNAs treatment. (D) Quantification of the images in C. (E) Representative Western blot for PHLPP1 in hPDLSCs following siRNAs treatment and quantification of the images. (F) Quantification of the images in E. (G) Representative Western blot for PHLPP1 in hPDLSCs following Calpeptin treatment. (H) Quantification of the images in G. (I) Representative Western blot for CAPN1, ERK1/2, and p-ERK1/2 in hPDLSCs following PD98059 or Calpeptin treatment. (J) Quantification of the images in J. (K) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following increasing NSC45586 doses treatment. (L) Quantification of the images in J. (M) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following siPHLPP1 treatment. (N) Quantification of the images in M. (O) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following si CAPN1 or si CAPN1 combined with NSC45586 treatment. (P) Quantification of the images in O. Mean ± SD was employed to express all data (ns P > .05, ∗ P < .05, ∗∗ P < .01, *** P < .001, **** P < .0001).

    Techniques Used: Western Blot, Transfection



    Similar Products

    pd98059  (MedChemExpress)
    96
    MedChemExpress pd98059
    CAPN1 facilitated the osteogenic differentiation of hPDLSCs through the ERK signalling pathway . (A) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs with or without lentivirus transfection. (B) Quantification of the images in A. (C) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs following siRNAs treatment. (D) Quantification of the images in C. (E) Representative Western blot for PHLPP1 in hPDLSCs following siRNAs treatment and quantification of the images. (F) Quantification of the images in E. (G) Representative Western blot for PHLPP1 in hPDLSCs following Calpeptin treatment. (H) Quantification of the images in G. (I) Representative Western blot for CAPN1, ERK1/2, and p-ERK1/2 in hPDLSCs following <t>PD98059</t> or Calpeptin treatment. (J) Quantification of the images in J. (K) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following increasing NSC45586 doses treatment. (L) Quantification of the images in J. (M) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following siPHLPP1 treatment. (N) Quantification of the images in M. (O) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following si CAPN1 or si CAPN1 combined with NSC45586 treatment. (P) Quantification of the images in O. Mean ± SD was employed to express all data (ns P > .05, ∗ P < .05, ∗∗ P < .01, *** P < .001, **** P < .0001).
    Pd98059, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd98059/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    pd98059 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    cat#  (MedChemExpress)
    96
    MedChemExpress cat#
    CAPN1 facilitated the osteogenic differentiation of hPDLSCs through the ERK signalling pathway . (A) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs with or without lentivirus transfection. (B) Quantification of the images in A. (C) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs following siRNAs treatment. (D) Quantification of the images in C. (E) Representative Western blot for PHLPP1 in hPDLSCs following siRNAs treatment and quantification of the images. (F) Quantification of the images in E. (G) Representative Western blot for PHLPP1 in hPDLSCs following Calpeptin treatment. (H) Quantification of the images in G. (I) Representative Western blot for CAPN1, ERK1/2, and p-ERK1/2 in hPDLSCs following <t>PD98059</t> or Calpeptin treatment. (J) Quantification of the images in J. (K) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following increasing NSC45586 doses treatment. (L) Quantification of the images in J. (M) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following siPHLPP1 treatment. (N) Quantification of the images in M. (O) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following si CAPN1 or si CAPN1 combined with NSC45586 treatment. (P) Quantification of the images in O. Mean ± SD was employed to express all data (ns P > .05, ∗ P < .05, ∗∗ P < .01, *** P < .001, **** P < .0001).
    Cat#, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cat#/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    cat# - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    thyca ko dectin1 pd98059 group  (MedChemExpress)
    96
    MedChemExpress thyca ko dectin1 pd98059 group
    CAPN1 facilitated the osteogenic differentiation of hPDLSCs through the ERK signalling pathway . (A) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs with or without lentivirus transfection. (B) Quantification of the images in A. (C) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs following siRNAs treatment. (D) Quantification of the images in C. (E) Representative Western blot for PHLPP1 in hPDLSCs following siRNAs treatment and quantification of the images. (F) Quantification of the images in E. (G) Representative Western blot for PHLPP1 in hPDLSCs following Calpeptin treatment. (H) Quantification of the images in G. (I) Representative Western blot for CAPN1, ERK1/2, and p-ERK1/2 in hPDLSCs following <t>PD98059</t> or Calpeptin treatment. (J) Quantification of the images in J. (K) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following increasing NSC45586 doses treatment. (L) Quantification of the images in J. (M) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following siPHLPP1 treatment. (N) Quantification of the images in M. (O) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following si CAPN1 or si CAPN1 combined with NSC45586 treatment. (P) Quantification of the images in O. Mean ± SD was employed to express all data (ns P > .05, ∗ P < .05, ∗∗ P < .01, *** P < .001, **** P < .0001).
    Thyca Ko Dectin1 Pd98059 Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/thyca ko dectin1 pd98059 group/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    thyca ko dectin1 pd98059 group - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    item number hy  (MedChemExpress)
    96
    MedChemExpress item number hy
    CAPN1 facilitated the osteogenic differentiation of hPDLSCs through the ERK signalling pathway . (A) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs with or without lentivirus transfection. (B) Quantification of the images in A. (C) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs following siRNAs treatment. (D) Quantification of the images in C. (E) Representative Western blot for PHLPP1 in hPDLSCs following siRNAs treatment and quantification of the images. (F) Quantification of the images in E. (G) Representative Western blot for PHLPP1 in hPDLSCs following Calpeptin treatment. (H) Quantification of the images in G. (I) Representative Western blot for CAPN1, ERK1/2, and p-ERK1/2 in hPDLSCs following <t>PD98059</t> or Calpeptin treatment. (J) Quantification of the images in J. (K) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following increasing NSC45586 doses treatment. (L) Quantification of the images in J. (M) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following siPHLPP1 treatment. (N) Quantification of the images in M. (O) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following si CAPN1 or si CAPN1 combined with NSC45586 treatment. (P) Quantification of the images in O. Mean ± SD was employed to express all data (ns P > .05, ∗ P < .05, ∗∗ P < .01, *** P < .001, **** P < .0001).
    Item Number Hy, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/item number hy/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    item number hy - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    CAPN1 facilitated the osteogenic differentiation of hPDLSCs through the ERK signalling pathway . (A) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs with or without lentivirus transfection. (B) Quantification of the images in A. (C) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs following siRNAs treatment. (D) Quantification of the images in C. (E) Representative Western blot for PHLPP1 in hPDLSCs following siRNAs treatment and quantification of the images. (F) Quantification of the images in E. (G) Representative Western blot for PHLPP1 in hPDLSCs following Calpeptin treatment. (H) Quantification of the images in G. (I) Representative Western blot for CAPN1, ERK1/2, and p-ERK1/2 in hPDLSCs following PD98059 or Calpeptin treatment. (J) Quantification of the images in J. (K) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following increasing NSC45586 doses treatment. (L) Quantification of the images in J. (M) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following siPHLPP1 treatment. (N) Quantification of the images in M. (O) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following si CAPN1 or si CAPN1 combined with NSC45586 treatment. (P) Quantification of the images in O. Mean ± SD was employed to express all data (ns P > .05, ∗ P < .05, ∗∗ P < .01, *** P < .001, **** P < .0001).

    Journal: International Dental Journal

    Article Title: Calpain-1 Potentiates Periodontal Regeneration via PHLPP1-ERK-Driven Osteogenesis in Periodontal Ligament Stem Cells

    doi: 10.1016/j.identj.2025.109309

    Figure Lengend Snippet: CAPN1 facilitated the osteogenic differentiation of hPDLSCs through the ERK signalling pathway . (A) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs with or without lentivirus transfection. (B) Quantification of the images in A. (C) Representative Western blot for CAPN1, p-ERK1/2, and ERK1/2 in hPDLSCs following siRNAs treatment. (D) Quantification of the images in C. (E) Representative Western blot for PHLPP1 in hPDLSCs following siRNAs treatment and quantification of the images. (F) Quantification of the images in E. (G) Representative Western blot for PHLPP1 in hPDLSCs following Calpeptin treatment. (H) Quantification of the images in G. (I) Representative Western blot for CAPN1, ERK1/2, and p-ERK1/2 in hPDLSCs following PD98059 or Calpeptin treatment. (J) Quantification of the images in J. (K) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following increasing NSC45586 doses treatment. (L) Quantification of the images in J. (M) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following siPHLPP1 treatment. (N) Quantification of the images in M. (O) Representative Western blot for PHLPP1, ERK1/2, p-ERK1/2 in hPDLSCs following si CAPN1 or si CAPN1 combined with NSC45586 treatment. (P) Quantification of the images in O. Mean ± SD was employed to express all data (ns P > .05, ∗ P < .05, ∗∗ P < .01, *** P < .001, **** P < .0001).

    Article Snippet: PDLSCs were cultured separately with 100 μM Calpeptin (MedChemExpress), 15 μM PD98059 (MedChemExpress), or equivalent DMSO (vehicle) in osteogenic medium for 3 days and washed twice with PBS before total protein extraction.

    Techniques: Western Blot, Transfection